Table 2 Glycemic parameters and medication status in the study populations.

From: Baseline clinical and biochemical profiles of type 2 diabetes patients enrolled in a lifestyle management program in India, a cross-sectional study

Parameter

Total

Males

Females

p value

OR (CI)*

HbA1c (%); n = 18,950

 < 7

5681 (30.0)

3697 (30.2)

1984 (29.5)

0.33

1.01 (0.99–1.04)

 ≥ 7

13,269 (70.0)

8536 (69.8)

4733 (70.5)

Fasting Blood Glucose (mg/dl); n = 18,182

70–100

2433 (13.4)

1619 (13.9)

814 (12.5)

0.01

1.04 (1.01–1.07)

 > 100

15,749 (86.6)

10,068 (86.1)

5681 (87.5)

Postprandial Blood Glucose (mg/dl); n = 12,610

 < 140

4306 (34.1)

2723 (33.9)

1583 (34.6)

0.46

0.99 (0.96–1.02)

 ≥ 140

8304 (65.9)

5307 (66.1)

2997 (65.4)

Fasting Insulin (mIU/L); n = 15,974

 < 2512

15,184 (95.1)

9817 (95.5)

5367 (94.1)

 < 0.001

1.14 (1.01–1.20)

 ≥ 25

790 (4.9)

455 (4.4)

335 (5.9)

HOMA-IR; n = 15,605

 < 2.511

7150 (45.8)

4895 (48.9)

2255 (40.3)

 < 0.001

1.13 (1.11–1.16)

 ≥ 2.5

8455 (54.2)

5111 (51.1)

3344 (59.7)

Medication Status; n = 18,950

 On OHA

12,071 (63.7)

7746 (63.3)

4325 (64.4)

 < 0.001

 

 On insulin

746 (3.9)

478 (3.9)

268 (4.0)

 Both OHA and insulin

2379 (12.6)

1404 (11.5)

975 (14.5)

 Drug Naïve

3754 (19.8)

2605 (21.3)

1149 (17.1)

  1. The data are presented as frequencies and percentages; OHA, oral hypoglycemic agents; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; HbA1c, glycated hemoglobin; references11,12 for corresponding parameter cutoff values; *Reference—female.
Back to article page